Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$28.94 USD
+0.03 (0.10%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $28.92 -0.02 (-0.07%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARWR 28.94 +0.03(0.10%)
Will ARWR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ARWR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARWR
Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates
ARWR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ARWR
Buy Rating Affirmed: Arrowhead Pharmaceuticals’ Advancements in RNAi Pulmonary Therapeutics Signal Market Growth Potential
Crowdstrike Catalyst For A Needed Reset
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CSL (OtherCMXHF) and Arrowhead Pharmaceuticals (ARWR)
TD Cowen Reaffirms Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)